COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

02/09/2024 - 01:30

Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment [...]

Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members

01/09/2024 - 23:57

WAKE FOREST, N.C. and ADELAIDE, Australia , Sept. 01, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had [...]

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01/09/2024 - 14:00

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE [...]

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

01/09/2024 - 10:27

Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients [...]

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

01/09/2024 - 09:51

Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten [...]

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

31/08/2024 - 09:54

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials testing multi- [...]

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

31/08/2024 - 05:56

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Avricore Grants Options

31/08/2024 - 03:29

VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) today announces that the Company’s board of directors has approved the granting of stock [...]

Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024

30/08/2024 - 22:35

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

30/08/2024 - 22:30

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences [...]

Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus

30/08/2024 - 22:30

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: [...]

Receipt of Nasdaq Delisting Determination - Plans to Appeal

30/08/2024 - 22:30

August 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage [...]

Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

30/08/2024 - 22:10

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company [...]

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

30/08/2024 - 22:05

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee [...]

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

30/08/2024 - 22:05

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications - No new safety signals observed at [...]

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

30/08/2024 - 22:00

Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August [...]

Fagron’s share buy-back program: Weekly update

30/08/2024 - 18:34

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37 [...]

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

30/08/2024 - 17:07

Please see enclosed pdf. Attachment 30082024_trading_in_shares_PRM

Total number of shares and voting rights in Zealand Pharma on August 30, 2024

30/08/2024 - 17:00

Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 [...]